Table 2. Hazard ratios and incidence rates (per 1000 person-year) for the primary and secondary endpoints according to low-density lipoprotein cholesterol response to statin therapy.
| Groups (n=1029) | CVD events (n) | Rate of CVD events (per 1000 person-years) | HR (adjusted)a (95%CI) | p-value | |
|---|---|---|---|---|---|
| MACE | Optimal | 40 | 17 | 1 | <0.001 |
| Suboptimal | 299 | 102 | 3.99 (2.66–6.01) | ||
| Cardiovascular death | Optimal | 6 | 2.6 | 1 | 0.30 |
| Suboptimal | 29 | 9.9 | 1.93 (0.55–6.74) | ||
| Reinfarction | Optimal | 4 | 1.7 | 1 | <0.001 |
| Suboptimal | 89 | 30.5 | 18.17 (5.72–57.6) | ||
| Recurrent myocardial infarction | Optimal | 25 | 10.7 | 1 | <0.001 |
| Suboptimal | 235 | 80.7 | 5.44 (3.20–9.23) | ||
| Target vessel revascularization, n (%) | Optimal | 38 | 16.4 | 1 | <0.001 |
| Suboptimal | 283 | 97.2 | 4.04 (2.66–6.14) |
a
The multivariable Cox regression models for MACE, cardiovascular death, reinfarction, recurrent myocardial infarction, and target vessel revascularization were adjusted for age, hypertension, prior myocardial infarction, prior coronary revascularization, baseline LDL-C, baseline total cholesterol, baseline triglyceride, baseline HDL-C, on-treatment LDL-C, and hs-CRP levels. LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; MACE: major adverse cardiovascular events. Bold values indicate statistical significance at the p<0.05 level.